Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes.
Takayama H, Misu H, Iwama H, Chikamoto K, Saito Y, Murao K, Teraguchi A, Lan F, Kikuchi A, Saito R, Tajima N, Shirasaki T, Matsugo S, Miyamoto K, Kaneko S, Takamura T. Takayama H, et al. Among authors: tajima n. J Biol Chem. 2014 Jan 3;289(1):335-45. doi: 10.1074/jbc.M113.479386. Epub 2013 Nov 20. J Biol Chem. 2014. PMID: 24257750 Free PMC article.
Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle.
Misu H, Takayama H, Saito Y, Mita Y, Kikuchi A, Ishii KA, Chikamoto K, Kanamori T, Tajima N, Lan F, Takeshita Y, Honda M, Tanaka M, Kato S, Matsuyama N, Yoshioka Y, Iwayama K, Tokuyama K, Akazawa N, Maeda S, Takekoshi K, Matsugo S, Noguchi N, Kaneko S, Takamura T. Misu H, et al. Among authors: tajima n. Nat Med. 2017 Apr;23(4):508-516. doi: 10.1038/nm.4295. Epub 2017 Feb 27. Nat Med. 2017. PMID: 28263310
Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells.
Ishikura K, Misu H, Kumazaki M, Takayama H, Matsuzawa-Nagata N, Tajima N, Chikamoto K, Lan F, Ando H, Ota T, Sakurai M, Takeshita Y, Kato K, Fujimura A, Miyamoto K, Saito Y, Kameo S, Okamoto Y, Takuwa Y, Takahashi K, Kidoya H, Takakura N, Kaneko S, Takamura T. Ishikura K, et al. Among authors: tajima n. Diabetologia. 2014 Sep;57(9):1968-76. doi: 10.1007/s00125-014-3306-9. Epub 2014 Jul 3. Diabetologia. 2014. PMID: 24989996
Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10).
Kamiya H, Himeno T, Watarai A, Baba M, Nishimura R, Tajima N, Nakamura J. Kamiya H, et al. Among authors: tajima n. J Diabetes Investig. 2024 Feb;15(2):247-253. doi: 10.1111/jdi.14105. Epub 2024 Jan 12. J Diabetes Investig. 2024. PMID: 38213265 Free PMC article.
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Lu Y, Liang S, Hong Y, Tajima N, Patel K, Li H, Wada DR, Greenberg J, Petrich A, Zebger-Gong H, Shuster D, Vaddady P. Lu Y, et al. Among authors: tajima n. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):23-28. doi: 10.1002/psp4.13058. Epub 2023 Nov 1. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37915242 Free PMC article. Clinical Trial.
Structural insights into NMDA receptor pharmacology.
Zhou C, Tajima N. Zhou C, et al. Among authors: tajima n. Biochem Soc Trans. 2023 Aug 31;51(4):1713-1731. doi: 10.1042/BST20230122. Biochem Soc Trans. 2023. PMID: 37431773 Free PMC article. Review.
494 results